Health Technology Dr. Reddy's Laboratories Ltd. Business Summary
Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services & Active Ingredients, Proprietary Products, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services & Active Ingredients segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research and development of differentiated formulations. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.
Financial Highlights
Mar 2022
INR USD Revenue 214,391M 2,877.35M Gross Profit 107,643M 1,444.68M Operating income 34,483M 462.79M Income before tax 31,595M 424.03M Net income 23,568M 316.30M EBITDA 46,307M 621.49M Diluted EPS 141.68 1.90 Dividends Per Share 30 0.40 Total Assets 292,827M 3,864.42M Total liabilities 102,300M 1,350.04M Total equity 190,527M 2,514.37M Operating cash flow 27,636M 370.90M Currency in INR Currency in USD
Historical Data Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Revenue
142,028M
153,851M
174,600M
189,722M
214,391M
Gross Profit
71,189M
78,008M
88,078M
96,342M
107,643M
Operating income
11,182M
19,584M
28,637M
32,028M
34,483M
Income before tax
13,997M
22,005M
17,471M
25,933M
31,595M
Net income
9,806M
18,795M
19,498M
17,238M
23,568M
EBITDA
22,892M
31,774M
41,109M
44,824M
46,307M
Diluted EPS
59.01
113.09
117.39
103.64
141.68
Dividends Per Share
20
20
25
25
30
Total Assets
225,604M
225,427M
232,241M
265,491M
292,827M
Total liabilities
99,144M
85,230M
77,253M
92,429M
102,300M
Total equity
126,460M
140,197M
154,988M
173,062M
190,527M
Operating cash flow
17,110M
27,878M
29,249M
35,602M
27,636M
Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Revenue
2,203.14M
2,199.67M
2,462.41M
2,555.69M
2,877.35M
Gross Profit
1,104.28M
1,115.31M
1,242.17M
1,297.79M
1,444.68M
Operating income
173.45M
280.00M
403.87M
431.44M
462.79M
Income before tax
217.12M
314.61M
246.39M
349.33M
424.03M
Net income
152.11M
268.71M
274.98M
232.20M
316.30M
EBITDA
355.10M
454.28M
579.76M
603.81M
621.49M
Diluted EPS
0.91
1.61
1.65
1.39
1.90
Dividends Per Share
0.31
0.28
0.35
0.33
0.40
Total Assets
3,459.03M
3,254.08M
3,069.88M
3,631.20M
3,864.42M
Total liabilities
1,520.10M
1,230.31M
1,021.17M
1,264.18M
1,350.04M
Total equity
1,938.92M
2,023.77M
2,048.71M
2,367.02M
2,514.37M
Operating cash flow
265.41M
398.58M
412.50M
479.58M
370.90M
Valuation Measures
Mar 2022
PER 30.30 ROA 8.44% ROE 12.96% Operating margin 16.08% Profit margin 10.99%
Key executives
Chief Executive Officer:
Erez Israeli
Chief Financial Officer:
Parag Agarwal
Chief Digital & Information Officer:
Mukesh Rathi
Secretary & Compliance Officer:
K. Randhir Singh
CEO-India & Emerging Markets Branded Markets:
M. V. Ramana Shareholders
APS Trust (20.6%)
Life Insurance Corporation of India (Investment Portfolio) (5.6%)
First Sentier Investors (Australia) IM Ltd. (3.5%)
REDDY SATISH KALLAM FAMILY (3.3%)
Exide Life Insurance Co. Ltd (2.9%)
SBI Funds Management Pvt Ltd. (2.6%)
Aditya Birla Sun Life Amc Ltd. (Investment Management) (2.0%)
BlackRock Fund Advisors (1.8%)
The Vanguard Group, Inc. (1.7%)
GIC Pte Ltd. (Investment Management) (1.7%)
Contact Details Website: http://www.drreddys.com Address:
Door No. 8-2-337,
Road No. 3,
Hyderabad,
500034,
India
Phone:
+91.40.49002900
Related Companies
Dr. Reddys Laboratories Ltd. /4 Brands/
Dr. Reddy's Laboratories Ltd. /2 Brands/
Nimbus Health GmbH
Dr. Reddy's Farmaceutica do Brasil Ltda.
Dr. Reddy's Employees ESOS Trust
Dr. Reddy's Research Foundation
BMS Laboratories Ltd.
Wockhardt Ltd. /Domestic Formulations Bus/
Imperial Credit Pvt Ltd.
Ducere Pharma LLC/Otc Bus/
UCB SA /Established Product Bus/
Dr. Reddy's Laboratories SA
Zenovus Biotech Pvt Ltd.
Regkinetics Services Ltd.
Dr. Reddy's Bio-Sciences Ltd.
Idea2Enterprises (India) Pvt Ltd.
Industrias Quimicas Falcon de Mexico SA de CV
Kunshan Rotam Reddy Pharmaceutical Co., Ltd.
Aurigene Discovery Technologies Ltd.
Perlecan Pharma Pvt Ltd.
Macred India Pvt Ltd.
BASF SE /Pharmaceutical Contract Manufacturing Unit/
Dowpharma /Small Molecules Business/
Laboratorios Litaphar SA
F. Hoffmann-La Roche Ltd. /Drug Ingredient Making Plant/
Trigenesis Therapeutics, Inc.
Competitors
Amneal Pharmaceuticals, Inc. Class A
Perrigo Co. Plc
KRKA dd
Teva Pharmaceutical Industries Limited
Hikma Pharmaceuticals Plc
Novartis AG
Pfizer Limited
Sanofi
Aurobindo Pharma Ltd
Cipla Ltd
Lupin Limited
Glenmark Pharmaceuticals Limited
Fresenius SE & Co. KGaA
Alkem Laboratories Ltd.
Zydus Lifesciences Limited
Nichi-Iko Pharmaceutical Co., Ltd.
Viatris, Inc.
Sanofi India Limited
Piramal Enterprises Ltd.
Sun Pharmaceutical Industries Limited
GlaxoSmithKline Pharmaceuticals Limited
Endo International Plc
Abbott India Limited
STADA Arzneimittel AG
Syngene International Ltd.
Granules India Limited
WuXi AppTec Co., Ltd. Class H
Lonza Group AG
Zhejiang Huahai Pharmaceutical Co., Ltd. Class A
Dishman Carbogen Amcis Ltd.
Copyright © 2022 FactSet Research Systems Inc. All rights reserved.
Last Updated on 5 Aug, 2022
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.
Celebrate our next chapter
Free access for everyone - Sep. 30
Find out more
By continuing to browse this website, you accept cookies which are used for several reasons such as personalizing content/ads and analyzing how this website is used. Please review our
Cookie Policy
to learn how you can update your cookie settings.
Accept & Continue
Close